PhenoPath, PLLC is a physician-owned specialty pathology practice and reference laboratory providing diagnostic and contract research services to pathology and oncology practices, hospitals, biopharmaceutical companies and research institutions in the U.S., Canada and around the world.
PhenoPath’s test menu includes a broad array of state-of-the-art immunohistochemistry, flow cytometry, fluorescence in situ hybridization and molecular assays as well as chromosome analysis.
PhenoPath now offers EGFR mutation testing using cell-free DNA isolated from plasma. Please see the links below for more information:
Visit Roche's cobas® EGFR mutation test web site for additional information:
PhenoPath at USCAP, Open House Event, PD-L1 (22C3 and 28-8) and EGFR T790M testing at PhenoPath, BAP1 and P16 FISH in malignant mesothelioma, and...Read More »
PhenoPath is proud to announce the release of FDA-approved PD-L1 IHC 22C3 pharmDx, for the semi-quantitative assessment of PD-L1 expression in non-small...Read More »
Effective Tuesday, November 17, 2015, PhenoPath is pleased to offer the Roche cobas® EGFR Mutation Test (v2), which will replace PhenoPath’s...Read More »